Physician profile
Junith M Thompson
NPI 1558413161
$8,581.47
in general payments reported to CMS, 2019-2025
31 companies · $824 in 2025
The $824 reported for 2025 was more than what 89% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $614 · 2021: $1,880 · 2022: $3,071 · 2023: $771 · 2024: $374 · 2025: $824.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,969.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,969.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,003.65 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Mayne Pharma Commercial LLC | $558.46 | 2021-2023 | |
| Sumitomo Pharma America, INC. | $509.86 | 2023-2025 | Myfembree, Gemtesa |
| Avion Pharmaceuticals | $422.12 | 2019-2021 | |
| Myovant Sciences INC. | $328.56 | 2021-2022 | |
| Daiichi Sankyo INC. | $316.31 | 2022-2024 | Injectafer |
| Pfizer INC. | $262.87 | 2021-2024 | |
| Novo Nordisk INC | $234.91 | 2025 | Wegovy |
| Pharmacosmos Therapeutics INC. | $166.50 | 2025 | Monoferric |
| Lupin INC. | $164.43 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $160.47 | 2021 | |
| Agile Therapeutics, INC. | $136.39 | 2021-2022 | |
| Allergan, INC. | $128.04 | 2019-2022 | |
| Hologic Sales and Service, LLC | $121.66 | 2019-2024 | Aptima, Thinprep 2000 Processor |
| Astellas Pharma US INC | $116.30 | 2019-2025 | Veozah |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Exeltis, USA INC. | $115.70 | 2021-2023 | Slynd |
| Organon LLC | $100.08 | 2023-2025 | Nexplanon |
| Lilly USA, LLC | $99.96 | 2021-2025 | Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $97.54 | 2019-2020 | |
| Medicem INC. | $93.49 | 2020-2022 | |
| Scynexis, INC. | $72.91 | 2022 | |
| Roche Diagnostics Corporation | $62.49 | 2019 | |
| Acella Pharmaceuticals, LLC | $56.99 | 2024-2025 | NP Thyroid 60 |
| Medtronic, INC. | $47.62 | 2025 | Interstim |
| Biohaven Pharmaceutical Holding Company LTD. | $46.29 | 2022 | |
| Azurity Pharmaceuticals, INC. | $37.04 | 2023 | Adthyza |
| Dysis Medical, INC. | $29.54 | 2019-2020 | |
| Currax Pharmaceuticals LLC | $27.44 | 2025 | Contrave |
| Mission Pharmacal Company | $24.88 | 2019 | |
| Dermira, INC. | $24.54 | 2019 | |
| Amag Pharmaceuticals, INC. | $14.43 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Junith Thompson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.